Skip to Content

Calcibind (cellulose sodium phosphate) Disease Interactions

There are 3 disease interactions with Calcibind (cellulose sodium phosphate):

Major

Cellulose sodium phosphate (applies to Calcibind) bone disease

Major Potential Hazard, High plausibility. Applicable conditions: Hyperparathyroidism, Osteoporosis, Malabsorption Syndrome

The use of cellulose sodium phosphate is contraindicated in patients with hyperparathyroidism (primary or secondary), bone disease (osteomalacia, osteoporosis), or low intestinal absorption and renal excretion of calcium. Cellulose sodium phosphate prevents absorption of intestinal calcium and can further increase the risk of calcium adsorption and bone disease.

References

  1. "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmaceutical Company, San Antonio, TX.
Major

Cellulose sodium phosphate (applies to Calcibind) electrolyte imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Nephrolithiasis, Malabsorption Syndrome, Hypocalcemia, Magnesium Imbalance, Phosphate Imbalance

The use of cellulose sodium phosphate is contraindicated in patients with undiagnosed hypophosphatemia (possible renal dysfunction or hypoparathyroidism), hypocalcemia (possible hypoparathyroidism, malabsorption syndrome), hypomagnesemia (further decrease may result in seizures), or hyperoxaluria (increased risk of renal oxalate stones).

References

  1. "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmaceutical Company, San Antonio, TX.
Major

Sodium salts (applies to Calcibind) sodium/water imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Hyponatremia, Hypokalemia, Congestive Heart Failure, Fluid Retention

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.

References

  1. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmaceutical Company, San Antonio, TX.
  3. "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals, San Clemente, CA.

Calcibind (cellulose sodium phosphate) drug interactions

There are 2 drug interactions with Calcibind (cellulose sodium phosphate)

More about Calcibind (cellulose sodium phosphate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.